Andrade Robert's Form 4 filing
Fennec Pharmaceuticals Inc. (FENC) · filed Jan 5, 2024
- Accession no.
- 0001415889-24-000781
- Filed
- Jan 5, 2024
- Trade date
- Jan 4-5, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $315.8K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Andrade RobertCIK 0001468308 | Officer (CHIEF FINANCIAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 4, 2024 | Common shares | SSaleDisposed | −15,000 | $10.64 | −$159,600 | 134,721 | Direct | |
| Jan 5, 2024 | Common shares | SSaleDisposed | −15,000 | $10.41 | −$156,150 | 119,721 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.